Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹194 Cr
Revenue (TTM)
₹717 Cr
Net Profit (TTM)
₹-355 Cr
ROE
-11.2 %
ROCE
-5.2 %
P/E Ratio
--
P/B Ratio
0.3
Industry P/E
33.74
EV/EBITDA
-3
Div. Yield
0 %
Debt to Equity
0.6
Book Value
₹36.2
EPS
₹-6.6
Face value
1
Shares outstanding
194,260,970
CFO
₹1,601.10 Cr
EBITDA
₹1,618.17 Cr
Net Profit
₹60.15 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nectar Lifescience
| -48.3 | -17.7 | -50.7 | -58.3 | -14.3 | -12.2 | -12.7 |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Nectar Lifescience
| -51.2 | 19.9 | 31.0 | -8.4 | 15.3 | 93.5 | -41.2 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Nectar Lifescience
|
10.0 | 194.3 | 717.1 | -355.1 | -35.0 | -17.7 | -- | 0.3 |
| 352.7 | 3,213.2 | 2,521.8 | 202.5 | 9.6 | 14.3 | 15.9 | 2.1 | |
| 989.6 | 12,119.0 | 2,512.3 | 543.7 | 28.3 | 19.3 | 22.3 | 3.8 | |
| 357.4 | 6,190.1 | 1,053.1 | 293.6 | 32.3 | 24.6 | 21.1 | 4.8 | |
| 1,025.1 | 10,733.1 | 1,158.7 | 309.6 | 31.9 | 17.3 | 34.3 | 5.7 | |
| 1,547.6 | 29,354.2 | 8,850.1 | 894.8 | 15.2 | 19.8 | 33.7 | 5.9 | |
| 12,433.0 | 15,953.0 | 1,575.1 | 179.1 | 14.9 | 11.4 | 89.1 | 9.6 | |
| 1,921.2 | 3,180.4 | 673.7 | 202.6 | 17.6 | 19.4 | 15.7 | 5.5 | |
| 784.3 | 3,617.1 | 588.5 | 102.9 | 22.1 | 12.7 | 35.6 | 4.3 | |
| 158.0 | 4,151.0 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 6.2 |
No Review & Analysis are available.
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime... axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company offers menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India. Read more
Incorporated
1995
Chairman
Sanjiv Goyal
Managing Director
Sanjiv Goyal
Headquarters
SAS Nagar Dist, Punjab
Website
Looking for more details about Nectar Lifesciences Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Nectar Lifesciences Ltd is ₹10.04 (NSE) and ₹10.00 (BSE) as of 02-Apr-2026 IST. Nectar Lifesciences Ltd has given a return of -14.3% in the last 3 years.
Since, TTM earnings of Nectar Lifesciences Ltd is negative, P/E ratio is not available.
The P/B ratio of Nectar Lifesciences Ltd is 0.28 times as on 02-Apr-2026, a 87 discount to its peers’ median range of 2.13 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
0.54
|
|
2024
|
135.18
|
0.63
|
|
2023
|
0.00
|
0.33
|
|
2022
|
21.53
|
0.50
|
|
2021
|
0.00
|
0.39
|
The 52-week high and low of Nectar Lifesciences Ltd are Rs 28.25 and Rs 9.30 as of 04-Apr-2026.
Nectar Lifesciences Ltd has a market capitalisation of ₹ 194 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Nectar Lifesciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹0.28
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.